2022-501138-49-00已完成2 期
ME-401 combined with rituximab-bendamustine for high-risk and rituximab with a 1:1 randomization to ME-401 for low-risk follicular lymphoma as primary treatment: a phase II study – NLG-FL5 (Follicular lymphoma and ME-401: FLAME)
Karolinska University Hospital7 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年10月14日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 7
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Coordinating Investigator
Scientific
Karolinska University Hospital
研究点 (7)
Loading locations...
相似试验
招募中
2 期
Treatment with venetoclax consolidated with ibrutinib and rituximab to increase the possibility of minimal residual disease in patient with chronic lymphotic leukemia2024-514687-33-00Ospedale San Raffaele S.r.l.55
招募中
1 期
Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer2023-509866-39-00Daiichi Sankyo Inc.76
招募中
2 期
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell LymphomaMantle Cell LymphomaNCT07261163Institute of Hematology & Blood Diseases Hospital, China37
招募中
2 期
Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS)2022-502743-35-00Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.52
招募中
3 期
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS 5)2023-503916-33-00ADC Therapeutics S.A.277